MedTrace Logo

ANC-501 in the Treatment of Adults With Major Depressive Disorder

NCT05439603 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-12-31

Study results available
· View outcomes & findings →

Summary

A Phase 2 Study of ANC-501 in the treatment of adults with Major Depressive Disorder

Conditions

Interventions

DRUG

ANC-501

Five 10 mg capsules per day

Sponsors & Collaborators

  • Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.

    lead INDUSTRY

Principal Investigators

  • Phil Perera, MD · Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-19
Primary Completion
2023-08-14
Completion
2023-10-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05439603 on ClinicalTrials.gov